DB04570 - Latamoxef
| Identification | |
|---|---|
| Name | Latamoxef |
| Accession Number | DB04570 |
| Type | small molecule |
| Description | Broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections. [PubChem] |
| Structure |
|
| Categories (*) | |
| Molecular Weight | 520.473 |
| Groups | approved |
| Monoisotopic Weight | 520.101246958 |
| Pharmacology | |
| Indication | Latamoxef is an oxacephem antibiotic usually grouped with the cephalosporins. It is used to treat bacterial infections. Latamoxef is primarily indicated in conditions like Bone and joint infection, GI infections, Gynecological infections, Meningitis, Respiratory tract infections, Septicaemia, Skin infections, Soft tissue infections, UTI. |
| Mechanism of action | Penicillins acylate the penicillin-sensitive transpeptidase C-terminal domain (the penicillin-binding protein) by opening the lactam ring. This inactivation of the enzyme prevents the formation of a cross-link of two linear peptidoglycan strands, inhibiting the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that amoxicllin interferes with an autolysin inhibitor. |
| Absorption | Rapidly absorbed after oral administration. |
| Protein binding | 40% |
| Biotransformation | Not Available |
| Route of elimination | Renal Excretion accounts for 75 % |
| Toxicity | Latamoxef produces potentially life-threatening effects which include Bleeding, Hypothrombinemia, Platelet dysfunctioning. which are responsible for the discontinuation of Latamoxef therapy. The symptomatic adverse reactions produced by Latamoxef are more or less tolerable and if they become severe, they can be treated symptomatically, these include Diarrhea, Skin rashes, Hematuria, Hyperuricemia, Pyuria, Raised serum creatinine. |
| Affected organisms | Not Available |
| Interactions | |
| Drug Interactions | Not Available |
| Food Interactions | Not Available |
Targets
| Penicillin-binding protein 3 | |
|---|---|
| Name | Penicillin-binding protein 3 |
| Gene Name | pbpC |
| Pharmacological action | yes |
| Actions | inhibitor |
| References |
|
| DTHybrid score | 0.575 |
| Penicillin-binding protein 1A | |
| Name | Penicillin-binding protein 1A |
| Gene Name | mrcA |
| Pharmacological action | unknown |
| Actions | inhibitor |
| References |
|
| DTHybrid score | 0.6505 |
| Penicillin-binding protein 1B | |
| Name | Penicillin-binding protein 1B |
| Gene Name | mrcB |
| Pharmacological action | unknown |
| Actions | inhibitor |
| References |
|
| DTHybrid score | 0.644 |
| Penicillin-binding protein 4 | |
| Name | Penicillin-binding protein 4 |
| Gene Name | dacB |
| Pharmacological action | unknown |
| Actions | inhibitor |
| References |
|
| DTHybrid score | 0.5365 |